OP0035 RISK OF FRAGILITY FRACTURE AFTER LONG-TERM DISCONTINUATION OF OSTEOPOROSIS TREATMENT IN POST-...
OP0035 RISK OF FRAGILITY FRACTURE AFTER LONG-TERM DISCONTINUATION OF OSTEOPOROSIS TREATMENT IN POST-MENOPAUSAL OSTEOPOROSIS WOMEN IN FRANCE: A POPULATION-BASED STUDY CONDUCTED ON THE NATIONWIDE CLAIM DATABASE (SNDS)
About this item
Full title
Author / Creator
Laborey, M. , Benmerad, M. , Lajoinie, A. , Samama, P. , Désaméricq, G. , Chelbani, L. and Briot, K.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Background:Bisphosphonates (BP) are first-line treatment for women with post-menopausal osteoporosis (PMO), with denosumab (Dmab) recommended second-line [1]. Recent recommendations mention long-term discontinuation (LTD) of BP, particularly in women with low fracture risk who have received treatment for 3 to 5 years [1, 2]. A recent study of US ad...
Alternative Titles
Full title
OP0035 RISK OF FRAGILITY FRACTURE AFTER LONG-TERM DISCONTINUATION OF OSTEOPOROSIS TREATMENT IN POST-MENOPAUSAL OSTEOPOROSIS WOMEN IN FRANCE: A POPULATION-BASED STUDY CONDUCTED ON THE NATIONWIDE CLAIM DATABASE (SNDS)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3086348353
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3086348353
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2024-eular.2841
